NCT06574984Completed
Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients
Descriptive Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients - An Observational Retrospective Study
Source: ClinicalTrials.gov · Last updated 17 Jun 2026
Brief summary (registry, in English)
The study has descriptive purposes, with aim of assessing how turoctocog alfa is used in the everyday practice and to provide a baseline for the management of haemophilia A and does not involve any change in the clinical management of participants. Data will be extrapolated from the existing paper based medical records and uploaded to an electronic database specifically created for the study. Baseline information/history will be recorded at time of switching from previous FVIII replacement therapy to turoctocog alfa from the enrolled participants and outcomes will be collected according to participants visit format.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 329 (actual)
- First submitted
- 26 Aug 2024
- Start date
- 10 Nov 2024
- Primary completion date
- 4 Nov 2025
- Lead sponsor
- Novo Nordisk A/S
- Diseases
- Haemophilia
- NCT number
- NCT06574984
What you commit to
- Study type: Observational
- Participants enrolled: 329
- From 10 Nov 2024 to the primary completion date, 4 Nov 2025
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with documented presence of any FVIII inhibitor
Other illness
- Patients diagnosed with coagulation disorders other than haemophilia A such as Von Willebrand disease
Who the study is looking for
- Paediatric and adult male patients
- On-demand and prophylactic patients with haemophilia A (any severity)
- Only previously treated patients (previous FVIII replacement therapy) will be included in the study
Sex: Male · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National centre for Hamophilia Coordinator of this site? Confirm its status | Baghdad | Iraq | Unknown status |
| - Coordinator of this site? Confirm its status | Baghdad | Iraq | Unknown status |
| Basrah Haemoplhilia centre Coordinator of this site? Confirm its status | Basra | Iraq | Unknown status |
| Hilla Haemophilia centre Coordinator of this site? Confirm its status | Hillah | Iraq | Unknown status |
| Karbala Haemophilia centre Coordinator of this site? Confirm its status | Karbala | Iraq | Unknown status |
| Kirkuk Centre for Cancer and Blood Disorders Coordinator of this site? Confirm its status | Kirkuk | Iraq | Unknown status |
| Najaf Haemophilia Centre Coordinator of this site? Confirm its status | Najaf | Iraq | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.